Vigonvita Life Sciences Co., Ltd. (SEHK: 2630)
Salud · Farmacéuticas · CN
72,65 HK$
-3,13 % hoy · +7,7 % 1 año
Vigonvita Life Sciences Co., Ltd. (SEHK: 2630) opera en la industria de farmacéuticas dentro del sector salud. Su valor en bolsa es de 1,55 mil M $ y tiene 315 empleados.
En los últimos doce meses la acción ha subido un 7,7 % y ha cotizado entre 52,00 y 134,90.
Tweenvest puntúa a Vigonvita Life Sciences Co., Ltd. en cuatro factores: calidad 31/100, valor 49/100. Su punto más fuerte es valor.
Evolución de la cotización de 2630
Cifras clave
- Capitalización
- 1,55 mil M $
- Ingresos (últ. 12 m)
- 31,98 M $
- PER
- -31,36
- BPA
- -2,59
- Rent. por dividendo
- —
- Beta (5 años)
- —
- Máximo 52 semanas
- 134,90 HK$
- Mínimo 52 semanas
- 52,00 HK$
- Volumen medio (3 m)
- —
- Acciones en circulación
- 167,60 M
- Empleados
- 315
- Próximos resultados
- —
Sobre Vigonvita Life Sciences Co., Ltd.
Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116, a RNA-dependent RNA polymerase inhibitor completed a Phase II clinical trial for the treatment of respiratory syncytial virus infection, as well as COVID-19 infections; TPN102, a novel antiepileptic drug, which is in Phase I clinical trial for the treatment of epilepsy; VV119, a multi-target serotonin-dopamine activity modulator, which is in Phase I clinical trial for the treatment of psychiatric disorders and schizophrenia; VV261, a novel nucleoside prodrug, which is in Phase I clinical trial for chikungunya, coronaviruses, influenza, and arena virus. In addition, it develops VV913, a novel investigational drug candidate for premature ejaculation; VV147 for the treatment of major depressive disorder; and VV207 for the treatment of adenovirus infection. The company was incorporated in 2013 and is headquartered in Suzhou, China.
- ISIN
- CNE1000076N3
- Fundada en
- 2013
- Cotiza desde
- 6 nov 2025
- Bolsa
- The Stock Exchange of Hong Kong Ltd.
- Divisa
- HKD
Otras empresas de farmacéuticas
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| Tibet Cheezheng Tibetan Medicine Co., Ltd.SZSE: 002287 | 1,60 mil M $ | 18,79 CN¥ | +0,54 % |
| Braveheart Bio, Inc.NasdaqGM: BRVE | 1,59 mil M $ | 19,49 $ | -0,66 % |
| Zhejiang CONBA Pharmaceutical Co.,Ltd.SHSE: 600572 | 1,57 mil M $ | 4,12 CN¥ | -0,48 % |
| Fujian Haixi Pharmaceuticals Co., Ltd.SEHK: 2637 | 1,57 mil M $ | 156,00 HK$ | -0,32 % |
| Marksans Pharma LimitedNSEI: MARKSANS | 1,53 mil M $ | 318,50 Rs | -0,47 % |
| PharmaBlock Sciences (Nanjing), Inc.SZSE: 300725 | 1,51 mil M $ | 43,40 CN¥ | -5,28 % |
| Xiamen Kingdomway Group CompanySZSE: 002626 | 1,51 mil M $ | 16,94 CN¥ | +0,89 % |
| Zhejiang Medicine Co., Ltd.SHSE: 600216 | 1,49 mil M $ | 10,51 CN¥ | -1,87 % |